C0292: The Role of Breast Cancer Cell Microparticles in Thrombogenicity, Angiogenesis and Apoptosis Following Chemotherapy

Abstract

Background: There is a lack of information regarding thromboembolism, thrombophilia and clinical management in different specific clinical settings such as vascular obstetric complication in women in the clinical practice. In this context, we are conducting a national registry of women in those situations, the so-called TEAM Project: a multicenter observational cohort study (see website: www.SETH.es). Methods: From 2009 since now, almost 60 Centers from Spain and also now, Uruguay have been including patients. The inclusion criteria are women with hormonal therapy or pregnancy-related thrombosis disease, vascular placental complications (VPC) or ischemic placental disease or ART and women with thrombophilia, that will undergo or not thromboprophylaxis during pregnancy or ART The study has been approved by the Ethical Committee of each Center. Among the primary outcomes, the investigation will focus on the incidence, prophylaxis and treatment of TD, hormonal or antineoplasic therapies or ART, as well as the management of vascular placental complications or thrombosis in those situations. Results: We have already recruited 329 patients from 20 Centers. 10% were women with thrombosis during pregnancy, 14% were women with VPC, 36% were included for thrombosis prophylaxis during pregnancy, 26% for prophylaxis of VPC during pregnancy and 2% had recurrent implantation failure. The thrombophilia test revealed that the most common risks factor were homozygous for F12 46C/T polymorphism, Factor V Leiden and high levels of Factor VIIIc. In general, 70% women received heparin for prophylaxis, some of them 30.6% received aspirin alone or in combination, of treatments during pregnancy. Heparin was used as treatment (11%) and prevention (89%), being tinzaparin 45% and enoxaparin (30%) the most indicated, along with bemiparin (20.5%) or dalteparin (4.5%). Clinical outcomes, in terms of relapse of thrombosis or VPC, showed only 1 case of thrombosis and 9 of CVG. Conclusions: The preliminary results from the Team Project reflects the clinical practice, and the differences among investigators in thromboprophylaxis, indication of thrombophilia testing and treatment in the clinical setting. Also new risk biological factors in women’s issues such as FVIIIc or homozygous for F12 46C/T polymorphism. The information of this ongoing registry will allow us to make the translation from clinical practice to clinical and biological investigation. Acknowledgement: The TEAM Project is partially sponsored by an unrestricted grant from LeopharmaTM. C0292 THE ROLE OF BREAST CANCER CELL MICROPARTICLES IN THROMBOGENICITY, ANGIOGENESIS AND APOPTOSIS FOLLOWING CHEMOTHERAPY